

Immunonkologische Therapien beim Urothelkarzinom der Harnblase – aktuelle Fortschritte und zukünftige Perspektiven

Merle Matzen & Mario Wolfgang Kramer

Literatur

1. DEAU Guidelines on MIBC - DISEASE MANAGEMENT - Uroweb. Uroweb - Eur Assoc Urol. (<https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/disease-management>). Zugegriffen am 19.06.2023
2. S3-Leitlinie Harnblasenkarzinom 2020. AWMF-Registernummer: 032/038OL. (https://register.awmf.org/assets/guidelines/032-038OLI_S3_Harnblasenkarzinom_2020-04-verlaengert.pdf). Zugegriffen am 19.06.2023
3. Balar AV et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. *Lancet Oncol* 2021; 22(7): 919–30
4. Bajorin DF et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med* 2021; 384: 2102–14
5. Galsky MD et al. Disease-free survival with longer follow-up from the phase 3 Checkmate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma. *SUO Annual Meeting*; 2021. Orlando, Florida
6. Galsky MD et al. Extended follow-up results from the CheckMate 274 trial. *J Clin Oncol* 2023; 41: LBA443
7. Extended CheckMate-274 Data Reinforce the Benefit of Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma. *ASCO Dly News*. (<https://dailynews.ascopubs.org/doi/10.1200/ADN.23.201299/full>). Zugegriffen am 06.08.2023
8. Basile G et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. *Clin Cancer Res Off J Am Assoc Cancer Res* 2022; 28: 5107–14

9. Szabados B et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. *Eur Urol* 2022; 82: 212–22
10. Powles T et al. A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). *J Clin Oncol* 2021; 39 (6): Suppl
11. Siefker-Radtke AO et al. 988TiP - KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC). *Ann Oncol* 2019; 30: v401
12. A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer. clinicaltrials.gov; 2023
13. Powles T et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; 22: 931–45
14. Powles T et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2020; 21(12): P1574–1588
15. Powles T et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. *NEJM* 2020; 383: 1218–30
16. Vuky J et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. *J Clin Oncol* 2020; 38: 2658–66
17. Eisenhauer EA et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45: 228–47
18. Galsky MD et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet Lond Engl* 2020; 395: 1547–57

19. Siefker-Radtke AO et al. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study. *J Clin Oncol* 2023; 41(16 Suppl): 4504

Metastasiertes Nierenzellkarzinom: Was spricht für die CPI/CPI und was für die CPI/TKI?

Jonas Wiegmann & Philipp Ivanyi

Literatur

1. Dutcher JP et al. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy. *Am Soc Clin Oncol Educ Book* 2020; 418–35
2. EAU Guidelines on RCC - INTRODUCTION - Uroweb. (<https://uroweb.org/guidelines/renal-cell-carcinoma>). Zugegriffen am 24.07.2023
3. Escudier B et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2019; 30: 706–20
4. Powles T et al. eUpdate – Renal Cell Carcinoma Treatment Recommendations. ESMO *Ann Oncol* 2021. (<https://www.esmo.org/guidelines/guidelines-by-topic/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-recommendations-4>). Zugegriffen am 24.07.2023
5. S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms (Version 4). (<https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/>). Zugegriffen am 24.07.2023
6. Heng DYC et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol Off J Am Soc Clin Oncol* 2009; 27: 5794–9
7. Méjean A et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. *N Engl J Med* 2018; 379: 417–27
8. Ivanyi P et al. Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC). *J Clin Oncol* 2016; 34: e16070

9. Motzer RJ et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2018; 378: 1277–90
10. Motzer RJ et al. Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib in advanced renal cell carcinoma. ESMO 2021 661P. (<https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/conditional-survival-and-5-year-follow-up-in-checkmate-214-first-line-nivolumab-ipilimumab-n-i-versus-sunitinib-s-in-advanced-renal-cell-car>). Zugegriffen am 24.07.2023
11. Rini BI et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380: 1116–27
12. Motzer RJ et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380: 1103–15
13. Motzer R et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med* 2021; 384: 1289–300
14. Choueiri TK et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2021; 384: 829–41
15. Motzer RJ et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). *J Clin Oncol* 2023; 41: 4502
16. Burotto M et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. *J Clin Oncol* 2023; 41: 603
17. Rini BI et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. *J Clin Oncol* 2023; 41: LBA4501
18. Bergerot CD et al. Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19. *The Oncologist* 2023; 28: 494–500
19. Cella D et al. Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial. *J Clin Oncol* 2021; 39: 285
20. Motzer RJ et al. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus

(EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). *J Clin Oncol* 2021; 39: 4502

21. Motzer RJ et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer* 2022; 128: 2085–97
22. Choueiri TK et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. *Ann Oncol* 2020; 31: 1030–9

Immuntherapeutika: Grundsätze der Therapie beim fortgeschrittenen Urothelkarzinom

Günter Niegisch

Literatur

1. Bajorin DF et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med* 2021; 384(22): 2102–14
2. Powles T et al. Avelumab Maintenance for Urothelial Carcinoma. Reply. *N Engl J Med* 2020; 383(25): 2483
3. Sridhar SS et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. *Journal of Clinical Oncology* 2023; 41(6_suppl): 508
4. Balar AV et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. *Lancet Oncol* 2017; 18(11): 1483–92
5. Balar AV et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet* 2017; 389(10064): 67–76
6. Bellmunt J et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med* 2017; 376(11): 1015–26
7. Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based

- chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016; 387(10031): 1909–20
8. Sharma P et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2017; 18(3): 312–22
 9. Powles, T et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2018; 391(10122): 748–57
 10. Powles T et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N Engl J Med* 2021; 384(12): 1125–35
 11. (<https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors>);. Zugegriffen am 23.06.2023
 12. (<https://www.ucir.org/immunotherapy-drugs/enfortumab-vedotin-ejfv>). Zugegriffen am 23.06.2023

Immunologische Biomarkertestung in urologischen Tumoren

Markus Eckstein

Literatur

1. Ljungberg B et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol* 2022; 82(4): 399–410
2. Witjes JA et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. *Eur Urol* 2021; 79(1): 82–104
3. Bajorin DF et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med* 2021; 384(22): 2102–14
4. Choueiri TK et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *N Engl J Med* 2021; 385(8): 683–94
5. Powles T et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2018; 391(10122): 748–57
6. Powles T et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; 22(7): 931–45

7. Eckstein M et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. *Eur J Cancer* 2019; 106: 234–43
8. Eckstein M et al. PD-L1 assessment in urothelial carcinoma: a practical approach. *Ann Transl Med* 2019; 7(22): 690
9. Erlmeier F et al. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. *Eur Urol* 2023; 83(2): 133–42

Langzeiterfolgsrate der Harnröhrenplastik mit Mundschleimhaut mittels ventral onlay

Mikhail Borisenkov, Abhishek Pandey

Literatur

1. Alwaal A et al. Epidemiology of urethral strictures. *Transl Androl Urol* 2014; 3(2): 209–13

Der Nachweis eines Isochromosoms i in malignen Keimzelltumoren mittels qPCR

Simon Filmar

Literatur

1. Trabert B et al. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. *Andrology* 2015; 3: 4–12
2. Ulbright TM et al. Germ cell tumours. In: Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (Hrsg.): *The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs - Part A*. 4. Auflage; International Agency for Research of Cancer, Lyon 2016, 189–226
3. Verdorfer I. Genetik der testikulären Keimzelltumoren. *Pathologe* 2014; 35: 218–23
4. Oosterhuis JW & Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. *Nat Rev Cancer* 2005; 5: 210–22
5. Atkin NB & Baker MC. i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis? *Cancer Genet Cytogenet* 1983; 19: 199–204

6. Mertens F et al. Isochromosomes in neoplasia. *Genes Chromosomes Cancer* 1994; 10: 221–30
7. Heinonen K et al. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. *Br J Haematol* 1996; 93: 677–80
8. Van Kessel AG et al. Trisomy 12 resulting from isochromosomes of both 12p and 12q in a case of B-CLL. *Cancer Genet Cytogenet* 1999; 108: 85–6
9. Izumi K & Krantz ID. Pallister-Killian syndrome. *Am J Med Genet C Semin Med Genet* 2014; 166C: 406–413
10. Suijkerbuijk RF et al. Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ cell tumors revealed by fluorescence in situ hybridization. *Cancer Genet Cytogenet* 1993; 70: 85–93
11. Dieckmann KP et al. Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours. *Eur Urol* 2017; 71: 213–20
12. Kum JB et al. Molecular genetic evidence supporting the origin of somatic-type malignancy and teratoma from the same progenitor cell. *Am J Surg Pathol* 2012; 36: 1849–56
13. Wehle D et al. Fluorescence in situ hybridization of 12p in germ cell tumors using a bacterial artificial chromosome clone 12p probe on paraffin-embedded tissue: clinical test validation. *Cancer Genet Cytogenet* 2008; 183: 99–104
14. Zafarana G et al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. *Oncogene* 2003; 22: 7695–701
15. Ottesen AM et al. High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. *Genes Chromosomes Cancer* 2003; 38: 117–25
16. Litchfield K et al. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. *Nat Commun* 2015; 6: 5973
17. Bosl GJ et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. *J Natl Cancer Inst* 1997; 86: 349–55
18. Buljubašić R et al. Epigenetics and testicular germ cell tumors. *Gene* 2018; 661: 22–33
19. Shen H et al. Integrated molecular characterization of testicular germ cell tumors. *Cell Rep* 2018; 23: 3392–406
20. Hanna NH & Einhorn LH. Testicular cancer - discoveries and updates. *N Engl J Med* 2014; 371: 2005–16